{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:52:15Z","timestamp":1785552735788,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00210-024-02955-6","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T08:02:19Z","timestamp":1706169739000},"page":"5253-5264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1007","volume":"397","author":[{"given":"Chengjie","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinfang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2955_CR1","doi-asserted-by":"publisher","first-page":"102393","DOI":"10.1016\/j.ctrv.2022.102393","volume":"106","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Nagasaka M (2022) A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev 106:102393. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102393","journal-title":"Cancer Treat Rev"},{"key":"2955_CR2","doi-asserted-by":"publisher","first-page":"1203471","DOI":"10.3389\/fimmu.2023.1203471","volume":"14","author":"JE Agrusa","year":"2023","unstructured":"Agrusa JE, Egress ER, Lowe EJ (2023) Brentuximab vedotin use in pediatric anaplastic large cell lymphoma. Front Immunol 14:1203471. https:\/\/doi.org\/10.3389\/fimmu.2023.1203471","journal-title":"Front Immunol"},{"issue":"6","key":"2955_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1200\/jco.1992.10.6.995","volume":"10","author":"LJ Ayash","year":"1992","unstructured":"Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E 3rd (1992) Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 10(6):995\u20131000. https:\/\/doi.org\/10.1200\/jco.1992.10.6.995","journal-title":"J Clin Oncol"},{"issue":"10310","key":"2955_CR4","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/s0140-6736(20)32207-8","volume":"398","author":"P Brice","year":"2021","unstructured":"Brice P, de Kerviler E, Friedberg JW (2021) Classical hodgkin lymphoma. Lancet 398(10310):1518\u20131527. https:\/\/doi.org\/10.1016\/s0140-6736(20)32207-8","journal-title":"Lancet"},{"issue":"16","key":"2955_CR5","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/cncr.28712","volume":"120","author":"KR Carson","year":"2014","unstructured":"Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the southern network on adverse reactions (SONAR) project. Cancer 120(16):2464\u201371. https:\/\/doi.org\/10.1002\/cncr.28712","journal-title":"Cancer"},{"issue":"18","key":"2955_CR6","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","volume":"387","author":"SM Castellino","year":"2022","unstructured":"Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM (2022) Brentuximab vedotin with chemotherapy in pediatric high-risk hodgkin\u2019s lymphoma. N Engl J Med 387(18):1649\u20131660. https:\/\/doi.org\/10.1056\/NEJMoa2206660","journal-title":"N Engl J Med"},{"issue":"12","key":"2955_CR7","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ (2015) Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory hodgkin lymphoma. Biol Blood Marrow Transplant 21(12):2136\u20132140. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2955_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","volume":"132","author":"ZA Corbin","year":"2017","unstructured":"Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA, Wood GS, Kim YH, Nagpal S (2017) Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis fungoides and s\u00e9zary syndrome. J Neurooncol 132(3):439\u2013446. https:\/\/doi.org\/10.1007\/s11060-017-2389-9","journal-title":"J Neurooncol"},{"issue":"12","key":"2955_CR9","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers13122898","volume":"13","author":"C Corti","year":"2021","unstructured":"Corti C, Giugliano F, Nicol\u00f2 E, Ascione L, Curigliano G (2021) Antibody-drug conjugates for the treatment of breast cancer. Cancers (Basel) 13(12):2898. https:\/\/doi.org\/10.3390\/cancers13122898","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2955_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/10428194.2021.1978090","volume":"63","author":"PA Costa","year":"2022","unstructured":"Costa PA, Espejo-Freire AP, Fan KC, Albini TA, Pongas G (2022) Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate. Leuk Lymphoma 63(1):239\u2013242. https:\/\/doi.org\/10.1080\/10428194.2021.1978090","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2955_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 66(4):309\u201325. https:\/\/doi.org\/10.3322\/caac.21341","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2955_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/1078-0432.Ccr-12-0290","volume":"19","author":"C Deng","year":"2013","unstructured":"Deng C, Pan B, O\u2019Connor OA (2013) Brentuximab vedotin. Clin Cancer Res 19(1):22\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-0290","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2955_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/nejm199103213241210","volume":"324","author":"JH Doroshow","year":"1991","unstructured":"Doroshow JH (1991) Doxorubicin-induced cardiac toxicity. N Engl J Med 324(12):843\u20135. https:\/\/doi.org\/10.1056\/nejm199103213241210","journal-title":"N Engl J Med"},{"issue":"8","key":"2955_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/10428194.2023.2220453","volume":"64","author":"MV Dubbini","year":"2023","unstructured":"Dubbini MV, De Marco L, Baldi L, Vignolo L, Ilariucci F (2023) Apoptotic colitis secondary to brentuximab vedotin: an immune mediated adverse event responsive to steroid treatment. Leuk Lymphoma 64(8):1497\u20131499. https:\/\/doi.org\/10.1080\/10428194.2023.2220453","journal-title":"Leuk Lymphoma"},{"key":"2955_CR15","unstructured":"FDA-Label-Brentuximab vedotin. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125388s107lbl.pdf. Accessed 9 Aug 2023"},{"issue":"18","key":"2955_CR16","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","volume":"123","author":"MD Gandhi","year":"2014","unstructured":"Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN (2014) Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood 123(18):2895\u20137. https:\/\/doi.org\/10.1182\/blood-2014-03-561878","journal-title":"Blood"},{"issue":"1","key":"2955_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-013-2192-z","volume":"72","author":"TH Han","year":"2013","unstructured":"Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A (2013) Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemother Pharmacol 72(1):241\u20139. https:\/\/doi.org\/10.1007\/s00280-013-2192-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2955_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 17(8):474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2955_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","volume":"125","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767\u201374. https:\/\/doi.org\/10.1007\/s10549-010-1278-0","journal-title":"Breast Cancer Res Treat"},{"key":"2955_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B, Hai X (2020) Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol 84:106601. https:\/\/doi.org\/10.1016\/j.intimp.2020.106601","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2955_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang L, Guo T, Zalkikar JN, Tiwari RC (2014) A review of statistical methods for safety surveillance. Ther Innov Regul Sci 48(1):98\u2013108. https:\/\/doi.org\/10.1177\/2168479013514236","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"2955_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12185-020-03039-w","volume":"113","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M (2021) Safety profile of brentuximab vedotin in japanese patients with relapsed\/refractory hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol 113(3):404\u2013412. https:\/\/doi.org\/10.1007\/s12185-020-03039-w","journal-title":"Int J Hematol"},{"issue":"10","key":"2955_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.clineuro.2012.03.019","volume":"114","author":"P Jalan","year":"2012","unstructured":"Jalan P, Mahajan A, Pandav V, Bekker S, Koirala J (2012) Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg 114(10):1335\u20137. https:\/\/doi.org\/10.1016\/j.clineuro.2012.03.019","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"2955_CR24","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1097\/cad.0000000000001191","volume":"33","author":"X Li","year":"2022","unstructured":"Li X, Chen G, Hu Y, Zhao B, Jiang J (2022) Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study. Anticancer Drugs 33(1):e228\u2013e234. https:\/\/doi.org\/10.1097\/cad.0000000000001191","journal-title":"Anticancer Drugs"},{"issue":"7","key":"2955_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40264-021-01069-9","volume":"44","author":"FA Lievano","year":"2021","unstructured":"Lievano FA, Scarazzini LJ, Tyczynski JE, Schubert CM, Renz CL (2021) Risk minimization of antibody-drug conjugates in oncology: a review. Drug Saf 44(7):733\u2013742. https:\/\/doi.org\/10.1007\/s40264-021-01069-9","journal-title":"Drug Saf"},{"issue":"5","key":"2955_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11883-016-0575-4","volume":"18","author":"T Mandviwala","year":"2016","unstructured":"Mandviwala T, Khalid U, Deswal A (2016) Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep 18(5):21. https:\/\/doi.org\/10.1007\/s11883-016-0575-4","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"2955_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijcard.2010.02.016","volume":"149","author":"CE Miguel","year":"2011","unstructured":"Miguel CE, Bestetti RB (2011) Primary cardiac lymphoma. Int J Cardiol 149(3):358\u201363. https:\/\/doi.org\/10.1016\/j.ijcard.2010.02.016","journal-title":"Int J Cardiol"},{"issue":"11","key":"2955_CR28","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.bbmt.2018.05.026","volume":"24","author":"A Nademanee","year":"2018","unstructured":"Nademanee A, Sureda A, Stiff P, Holowiecki J, Abidi M, Hunder N, Pecsok M, Uttarwar M, Purevjal I, Sweetenham J (2018) Safety analysis of brentuximab vedotin from the phase III AETHERA trial in hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant 24(11):2354\u20132359. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.026","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2955_CR29","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","volume":"124","author":"AK Ng","year":"2014","unstructured":"Ng AK (2014) Current survivorship recommendations for patients with hodgkin lymphoma: focus on late effects. Blood 124(23):3373\u20139. https:\/\/doi.org\/10.1182\/blood-2014-05-579193","journal-title":"Blood"},{"issue":"8","key":"2955_CR30","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/jco.2002.08.021","volume":"20","author":"AK Ng","year":"2002","unstructured":"Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM (2002) Long-term survival and competing causes of death in patients with early-stage hodgkin\u2019s disease treated at age 50 or younger. J Clin Oncol 20(8):2101\u20138. https:\/\/doi.org\/10.1200\/jco.2002.08.021","journal-title":"J Clin Oncol"},{"issue":"29","key":"2955_CR31","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2217\/fon-2020-0026","volume":"16","author":"L Nikolaenko","year":"2020","unstructured":"Nikolaenko L, Nademanee A (2020) Brentuximab vedotin and its use in the treatment of advanced hodgkin\u2019s lymphoma. Future Oncol 16(29):2273\u20132282. https:\/\/doi.org\/10.2217\/fon-2020-0026","journal-title":"Future Oncol"},{"issue":"1","key":"2955_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.transci.2013.12.001","volume":"50","author":"HA Ozkan","year":"2014","unstructured":"Ozkan HA, Bal C, Gulbas Z (2014) Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide. Transfus Apher Sci 50(1):46\u201352. https:\/\/doi.org\/10.1016\/j.transci.2013.12.001","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"2955_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"VB Pai","year":"2000","unstructured":"Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22(4):263\u2013302. https:\/\/doi.org\/10.2165\/00002018-200022040-00002","journal-title":"Drug Saf"},{"issue":"11","key":"2955_CR34","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ (2020) A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin Drug Saf 19(11):1505\u20131511. https:\/\/doi.org\/10.1080\/14740338.2020.1799975","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"2955_CR35","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.3390\/cancers13133126","volume":"13","author":"V Perrotti","year":"2021","unstructured":"Perrotti V, Caponio VCA, Mascitti M, Lo Muzio L, Piattelli A, Rubini C, Capone E, Sala G (2021) Therapeutic potential of antibody-drug conjugate-based therapy in head and neck cancer: a systematic review. Cancers (Basel) 13(13):3126. https:\/\/doi.org\/10.3390\/cancers13133126","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2955_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0002-9149(68)90250-6","volume":"22","author":"WC Roberts","year":"1968","unstructured":"Roberts WC, Glancy DL, DeVita VT Jr (1968) Heart in malignant lymphoma (hodgkin\u2019s disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides). a study of 196 autopsy cases. Am J Cardiol 22(1):85\u2013107. https:\/\/doi.org\/10.1016\/0002-9149(68)90250-6","journal-title":"Am J Cardiol"},{"key":"2955_CR37","doi-asserted-by":"publisher","first-page":"2359437","DOI":"10.1155\/2016\/2359437","volume":"2016","author":"Y Sabet","year":"2016","unstructured":"Sabet Y, Ramirez S, RosellCespedes E, Rensoli Velasquez M, Porres-Mu\u00f1oz M, Gaur S, Figueroa-Casas JB, Porres-Aguilar M (2016) Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory hodgkin\u2019s lymphoma. Case Rep Pulmonol 2016:2359437. https:\/\/doi.org\/10.1155\/2016\/2359437","journal-title":"Case Rep Pulmonol"},{"key":"2955_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/clep.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789\u2013802. https:\/\/doi.org\/10.2147\/clep.S365513","journal-title":"Clin Epidemiol"},{"issue":"9","key":"2955_CR39","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/cns.14215","volume":"29","author":"Y Shu","year":"2023","unstructured":"Shu Y, Ding Y, Liu L, Zhang Q (2023) Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system. CNS Neurosci Ther 29(9):2705\u20132716. https:\/\/doi.org\/10.1111\/cns.14215","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"2955_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, CarmagnaniPestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G (2022) Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 72(2):165\u2013182. https:\/\/doi.org\/10.3322\/caac.21705","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2955_CR41","doi-asserted-by":"publisher","first-page":"e35804","DOI":"10.7759\/cureus.35804","volume":"15","author":"K Thakkar","year":"2023","unstructured":"Thakkar K, Khurana S, Sun Y, Hembree TN (2023) Diabetic ketoacidosis and profound insulin resistance from brentuximab vedotin. Cureus 15(3):e35804. https:\/\/doi.org\/10.7759\/cureus.35804","journal-title":"Cureus"},{"issue":"5","key":"2955_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/cells11050803","volume":"11","author":"A Ungaro","year":"2022","unstructured":"Ungaro A, Tucci M, Audisio A, Di Prima L, Pisano C, Turco F, Delcuratolo MD, Di Maio M, Scagliotti GV, Buttigliero C (2022) Antibody-drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside. Cells 11(5):803. https:\/\/doi.org\/10.3390\/cells11050803","journal-title":"Cells"},{"key":"2955_CR43","unstructured":"Vedotin. F-L-B (2023) Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125388s107lbl.pdf. Accessed 9 Aug 2023"},{"issue":"24","key":"2955_CR44","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1182\/bloodadvances.2021004846","volume":"5","author":"J Yeh","year":"2021","unstructured":"Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat U (2021) Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv 5(24):5599\u20135607. https:\/\/doi.org\/10.1182\/bloodadvances.2021004846","journal-title":"Blood Adv"},{"issue":"19","key":"2955_CR45","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1002965","journal-title":"N Engl J Med"},{"issue":"18","key":"2955_CR46","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/jco.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20139. https:\/\/doi.org\/10.1200\/jco.2011.38.0410","journal-title":"J Clin Oncol"},{"issue":"9361","key":"2955_CR47","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/s0140-6736(03)12777-8","volume":"361","author":"L Yung","year":"2003","unstructured":"Yung L, Linch D (2003) Hodgkin\u2019s lymphoma. Lancet 361(9361):943\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(03)12777-8","journal-title":"Lancet"},{"issue":"7","key":"2955_CR48","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3390\/cancers14071650","volume":"14","author":"XR Zhang","year":"2022","unstructured":"Zhang XR, Chien PN, Nam SY, Heo CY (2022) Anaplastic large cell lymphoma: molecular pathogenesis and treatment. Cancers (Basel) 14(7):1650. https:\/\/doi.org\/10.3390\/cancers14071650","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2955_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","volume":"23","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Ding Y, Shu Y, Chen J (2023) A real-world disproportionality analysis of rucaparib: post-marketing pharmacovigilance data. BMC Cancer 23(1):745. https:\/\/doi.org\/10.1186\/s12885-023-11201-w","journal-title":"BMC Cancer"},{"issue":"2","key":"2955_CR50","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11010-020-03985-3","volume":"476","author":"H Zhou","year":"2021","unstructured":"Zhou H, Liu L, Ma X, Wang J, Yang J, Zhou X, Yang Y, Liu H (2021) RIP1\/RIP3\/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. Mol Cell Biochem 476(2):1233\u20131243. https:\/\/doi.org\/10.1007\/s11010-020-03985-3","journal-title":"Mol Cell Biochem"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-02955-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-02955-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-02955-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:32:23Z","timestamp":1718112743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-02955-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-02955-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"14 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"SPSS version 28.0 (IBM Corp., Armonk, NY, USA)","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistical software"}}]}}